Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsCameron Turtle is recorded as COO at Spyre Therapeutics, Inc. (SYRE) since June 21, 2023, CEO and Board Member at Spyre Therapeutics, Inc. (SYRE) and Board Member at Oruka Therapeutics, Inc. (ORKA) since August 29, 2024. The newest filing on record that lists Cameron Turtle as CEO and Board Member at Spyre Therapeutics, Inc. (SYRE) is dated April 10, 2026. Spyre Therapeutics, Inc. reported in an 8-K filed May 29, 2026 that Cameron Turtle was appointed Class I director, effective May 27, 2026. Oruka Therapeutics, Inc. reported in an 8-K filed December 11, 2025 that Cameron Turtle resigned as member of the Board of Directors, effective December 11, 2025. Oruka Therapeutics, Inc. reported in an 8-K filed September 5, 2024 that Cameron Turtle was appointed director (Class II), effective August 29, 2024. Equibles holds 9 filed executive changes naming Cameron Turtle; each is listed under recent activity with its source filing. The proxy statement of Spyre Therapeutics, Inc. reports total compensation of $6,707,361 for Cameron Turtle in fiscal 2025, including a base salary of $665,000. Disclosed compensation is on record for 4 fiscal years. Cameron Turtle has spoken on 2 investor events across 1 company, most recently for Spyre Therapeutics, Inc. on September 10, 2026. Spyre Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Spyre Therapeutics, Inc. includes Cameron Turtle, DPhil (CEO and Board Member), James Kastenmayer (CEO), Jeffrey M. Goldberg (CEO) and 7 others.
“The Company’s stockholders elected three Class I directors, Mark McKenna, Cameron Turtle, and Laurie Stelzer, each to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.”
“On December 11, 2025, Cameron Turtle resigned as a member of the Board of Directors (the "Board") of Oruka Therapeutics, Inc. ("Oruka" or the "Company").”
“Maybe to kick us off, could you start with a brief overview of the company before we jump into question sure so we're interested in what we hope to elevate the standard of care across a range of the large autoimmune markets we started initially an inflammatory bowel disease working on what we think are the three best…”
“The background for SPIRE is that we're working on a portfolio of therapies that we hope will elevate the standard of care in autoimmune disease.”
2024-08-29–present
2023-06-21–present
Proxy statement
Start not stated–present
Last confirmed April 30, 2021
Start not stated–present
Last confirmed April 10, 2026
Start not stated–present
Last confirmed April 10, 2026
2023-06-21–2023-11-22
Start not stated–2025-12-11
Biotechnology · Healthcare
CEO, Board Member, COO
2023-06-21–present
Biotechnology · Healthcare
Board Member
2024-08-29–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Spyre Therapeutics, Inc. (SYRE) | Chief Executive Officer | $665,000 | $6,707,361 |
| 2024 | Spyre Therapeutics, Inc. (SYRE) | Chief Executive Officer | $625,000 | $6,960,186 |
| 2023 | Spyre Therapeutics, Inc. (SYRE) | Chief Executive Officer | $272,850 | $15,919,545 |
| 2020 | BridgeBio Pharma, Inc. (BBIO) | Ph.D.\ Chief Strategy Officer | $400,000 | $4,561,482 |
